REGENXBIO Inc. (RGNX)

Market Cap	498.07M
Revenue (ttm)	155.78M
Net Income (ttm)	-175.57M
Shares Out	50.51M
EPS (ttm)	-3.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	619,026
Open	8.87
Previous Close	9.12
Day's Range	8.82 - 9.87
52-Week Range	5.04 - 13.48
Beta	1.11
Analysts	Strong Buy
Price Target	28.50 (+189.05%)
Earnings Date	Aug 7, 2025

About RGNX

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 17, 2015
• Employees: 353
• Stock Exchange: NASDAQ
• Ticker Symbol: RGNX
• Website: https://www.regenxbio.com

Financial Performance

In 2024, REGENXBIO's revenue was $83.33 million, a decrease of -7.66% compared to the previous year's $90.24 million. Losses were -$227.10 million, -13.81% less than in 2023.

Analyst Summary

According to 8 analysts, the average rating for RGNX stock is "Strong Buy." The 12-month stock price target is $28.5, which is an increase of 189.05% from the latest price.

Price Target

$28.5

(189.05% upside)

Analyst Consensus: Strong Buy